SBIR Award: Integrated BioTherapeutics to Create Therapeutic Multi-Specific Antibodies Using Technology from Zyngenia Integrated Biotherapeutics (IBT) has been awarded a Phase I Small Business Innovative Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division…

Integrated BioTherapeutics (IBT) has been awarded a Phase I Small Business Innovative Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the NIH. The company will receive $550,000 for work to take place…

Efforts to develop effective vaccines against Staphylococcus aureus (S. aureus) have been largely unsuccessful, in part due to the variety of virulence factors produced by this organism. Recently, researchers lead by Dr. Rajan Adhikari at IBT have published a paper…